Download PDF
Hamostaseologie 1985; 05(05/06): 174-177
DOI: 10.1055/s-0038-1655125
Originalarbeiten
Schattauer GmbH

Blutplättchen, Endothel und Tumorzellen

M. Steiner
1   Division of Hematology/Oncology, The Memorial Hospital, Pawtucket, and Brown University, Providence, RI/USA
› Author Affiliations
Further Information

Publication History

Publication Date:
22 June 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Wir haben uns um eine ausgeglichene Interpretation des Für und Wider einer Beteiligung der Ausscheidungsprodukte von Thrombozyten und Endothelzellen an der hämatogenen Metastasierung maligner Tumoren bemüht. Die Bilanz reicht jedoch nicht aus, um den Thrombozyten die dominierende Rolle bei der Aussaat von Tumorzellen zuzuschreiben. Zweifellos gibt es maligne Tumoren, deren hämatogene Ausbreitung in hohem Maße von den Sekretionsprodukten der Blutplättchen und Endothelzellen abhängt. Eine tabellarische Zusammenstellung derartiger Tumoren müßte allerdings erst noch erstellt werden und würde bruchstückhaft bleiben. Jedoch selbst innerhalb der speziellen Gruppe beeinflußbarer Tumoren bleibt fraglich, ob die Verabreichung antithrombozytärer Substanzen und/ oder PGI2-Agonisten mehr als eine nur nachgeordnete Rolle in der Hemmung einer Metastasenbildung zu spielen vermag. Die hämatogene Aussaat bösartiger Zellen stellt einen so multifaktoriell ausgelösten Prozeß dar, daß eine scharf fokussierte Therapie wohl kaum in der Lage sein wird, dieses Geschehen zu unterdrücken. Da jedoch keine großangelegten Studien entsprechender therapeutischer Maßnahmen an einem repräsentativen Querschnitt verschiedener Tumoren existieren, muß jeder seine eigenen Schlußfolgerungen aus den vorliegenden Daten ziehen.

 

  • LITERATUR

  • 1 Honn K. V, Bookman R. S, Marnett L. J. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins 21: 833-864 1981;
    CrossrefPubMedGoogle Scholar
  • 2 Dvorak H. F, Quay S. C, Orenstein N. S, Dvorak A. M, Hahn P, Bitzer A. M, Carvalho A. Tumor shedding and coagulation. Science 212: 923-924 1981;
    CrossrefPubMedGoogle Scholar
  • 3 Dvorak H. F, Orenstein N. S, Dvorak A. M. Tumor-secreted mediators and the tumor microenvironment: relationship to immunological surveillance. Lymphokines 02: 203-233 1981;
    PubMedGoogle Scholar
  • 4 Jones D. S, Wallace A. C, Fraser E. E. Sequence of events in experimental métastasés of Walker 256 tumor: light, immunofluorescent and electronmicroscopic observations. J. Natl. Cancer Inst 46: 493-504 1971;
    PubMedGoogle Scholar
  • 5 Gasic G. J, Gasic T. B, Stewart C. C. Antimetastatic effects associated with platelet reduction. Proc. Natl. Acad. Sci. (USA) 61: 46-52 1968;
    CrossrefPubMedGoogle Scholar
  • 6 Gasic G. J, Gasic T. B, Galanti N, Johnson T, Murphy S. Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int. J. Cancer 11: 704-718 1973;
    PubMedGoogle Scholar
  • 7 Gasic G. J, Koch P. A. G, Hsu B, Gasic T. B, Niewiarowski S. Thrombogenic activity of mouse and human tumors : effects on platelets, coagulation and fibrinolysis and possible significance for métastasés. Z. Krebsforsch 86: 263-277 1976;
    CrossrefPubMedGoogle Scholar
  • 8 Holme R, Oftebro R, Hovig T. In vitro interaction between cultured cells and human blood platelets. Thrombos. Haemostas 40: 89-102 1978;
    PubMedGoogle Scholar
  • 9 Pearlstein E, Ambrogio C, Gasic G, Karpatkin S. Inhibition of the platelet-aggregating activity of two human adenocarcinoma of the colon and an anaplastic immune tumor with a specific thrombin inhibitor: docusylarginine N-(3-ethyl-l,5-pentanediyl) amide. In: Interaction of Platelets and Tumor Cells. Jamieson G. A. (Ed.). Alan R. Liss; New York: 1982: 479-502.
    Google Scholar
  • 10 Gastpar H. Stickiness of platelets and tumor cells induced by drugs. Thromb. Diath. Haemorrh. Suppl. 42: 291-303 1979;
    PubMedGoogle Scholar
  • 11 Hara Y, Steiner M, Baldini M. Characterization of the platelet-aggregating activity of tumor cells. Cancer Res. 40: 1217-1222 1980;
    PubMedGoogle Scholar
  • 12 Gasic G. J, Gasic T. B. Plasma membrane vesicles as mediators of interactions between tumor cells and components of the hemostatic and immune systems. In: Interaction of Platelets and Tumor Cells. Jamieson G. A. (Ed.). Alan R. Liss; New York: 1982: 429-444.
    Google Scholar
  • 13 Karpatkin S, Smerling A, Pearlstein E. Plasma requirement for the aggregation of rabbit platelets by an aggregating material derived from SV40-transformed 3T3 fibroblasts. J. Lab. Clin. Med. 96: 994-1001 1980;
    PubMedGoogle Scholar
  • 14 Steiner M. Interaction of platelets and tumor cells. In: Interaction of Platelets and Tumor Cells. Jamieson G. A. (Ed.). Alan R. Liss; New York: 1982: 383-403.
    Google Scholar
  • 15 Honn K. V, Cavanaugh P, Evens C, Taylor J. D, Sloane B. I. Tumor cell-platelet aggregation: induced by cathepsin B-like proteinase and inhibited by prostacyclin. Science 217: 540-542 1982;
    CrossrefPubMedGoogle Scholar
  • 16 Schmidt M. B. Die Verbreitungswege der Karzinome und die Beziehung generalisierter Sarkome zu den leukämischen Neubildungen. G. Fischer; Stuttgart: 1903
    Google Scholar
  • 17 Wood Jr S. Pathogenesis of metastasis formation observed in vivo in the rabbit ear chamber. Arch. Path. 66: 550-568 1958;
    PubMedGoogle Scholar
  • 18 Hilgard P. The role of blood platelet in experimental métastasés. Brit. J. Cancer 28: 429-435 1973;
    CrossrefPubMedGoogle Scholar
  • 19 Gasic G, Gasic T, Galanti N, Johnson T, Murphy S. Platelet-tumor cell interactions in mice. The role of platelets in the spread of malignant disease. Int. J. Cancer 11: 704-718 1973;
    PubMedGoogle Scholar
  • 20 Poggi A, Polentarutti N, Donati M. B, Degaetano G, Garattini S. Blood coagulation changes in mice bearing Lewis lung carcinoma, a metastasizing tumor. Cancer Res. 37: 272-277 1977;
    PubMedGoogle Scholar
  • 21 Pearlstein E, Salk P. L, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastatic potential platelet aggregating activity of cell surface extracts and cell surface sialylation in 10 metastatic variant derivatives of a rat renal sarcoma cell line. Proc. Natl. Acad. Sci. (USA) 77: 4336-4339 1980;
    CrossrefPubMedGoogle Scholar
  • 22 Ambrus J. L, Ambrus C. M, Gastpar H. Studies on platelet aggregation in vivo: VI. Effect of a pyrimidopyrimidine derivative (RA-233) on tumor cell metastasis. J. Med. 09: 183-186 1978;
    PubMedGoogle Scholar
  • 23 Ambrus J. L, Ambrus C. M, Gastpar H. Studies on platelet aggregation and platelet interaction with tumor cells. In: Platelets: A Multidisciplinary Approach. De Gaetano G, Garattini S. (Eds.). Raven Press; New York: 1980: 467.
    Google Scholar
  • 24 Gastpar H, Ambrus J. L, Ambrus C. M. Platelet cancer cell interaction in metastasis formation. Platelet aggregation inhibitors: a possible approach to metastasis prevention. In: Interaction of Platelets and Tumor Cells. Jamieson G. A. (Ed.). Alan R. Liss; New York: 1982: 63-82.
    Google Scholar
  • 25 Hilgard P, Heller H, Schmidt C. G. The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL). Z. Krebsforsch. 86: 243-250 1976;
    CrossrefPubMedGoogle Scholar
  • 26 Schmahl D. Versuche zur Beeinflussung der Metastasierung autochthoner Hepatome bei Ratten mit Antikoagulantien. Arzneim. Forsch. 25: 1621-1623 1975;
    PubMedGoogle Scholar
  • 27 Atherton A, Busfield D, Hellmann K. The effects of an antimetastatic agent (±)l,2-bis(3,5-dioxopiperazin-l-yl) propane (ICRF 159) on platelet behaviour. Cancer Res. 35: 953-957 1975;
    PubMedGoogle Scholar
  • 28 Machado E. A, Gerard D. A, Mitchell J. R, Lozzio B. B, Lozzio C. B. Arrest and extravasation of neoplastic cells. Virchows Arch. Path. Anat. 396: 73-89 1982;
    CrossrefPubMedGoogle Scholar
  • 29 Honn K. V, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Science. 272: 1270-1272 1981;
    PubMedGoogle Scholar
  • 30 Honn K. V, Busse W. D, Sloane B. F. Prostacyclin and thromboxanes. Implications for their role in tumor cell metastasis. Biochem. Pharmacol. 32: 1-11 1983;
    PubMedGoogle Scholar
  • 31 Warren B. A, Vales O. The adhesion of thromboplastic tumour emboli to vessel walls in vivo. Brit. J. Exp. Path. 53: 301-313 1972;
    PubMedGoogle Scholar
  • 32 Kramer R. H, Nicolson G. L. Interactions of tumor cells with vascular endothelial cell monolayers: a model for metastatic invasion. Proc. Natl. Acad. Sci. (USA) 76: 5704-5708 1979;
    CrossrefPubMedGoogle Scholar
  • 33 Kramer R. H, Vogel K. G, Nicolson G. L. Tumor cell interaction with vascular endothelial cells and their extracellular matrix. In: Interaction of Platelets and Tumor Cells. Jamieson G. A. (Ed.). Alan R. Liss; New York: 1982: 333-501.
    Google Scholar
  • 34 Currie G. A. Platelet-derived growthfactor requirements for in vitro proliferation of normal and malignant mesenchymal cells. Brit. J. Cancer 43: 335-343 1981;
    CrossrefPubMedGoogle Scholar
  • 35 Eastment C. T, Sirbasku D. A. Platelet derived growth factor(s) for a hormone responsive rat mammary tumor cell line. J. Cell Physiol. 97: 17-27 1978;
    CrossrefPubMedGoogle Scholar
  • 36 Kohler N, Lipton A. Release and characterization of a growth factor for SV40 virustransformed cells from human platelets. Proc. Am. Assoc. Cancer Res. 18 (Abstr.): 244 1977;
    PubMedGoogle Scholar
  • 37 Hara J, Steiner M, Baldini M. Platelets as a source of growth promoting factor(s) for tumor cells. Cancer Res. 40: 1212-1216 1980;
    PubMedGoogle Scholar